<DOC>
	<DOCNO>NCT02101853</DOCNO>
	<brief_summary>This randomized phase III trial study well blinatumomab work compare standard combination chemotherapy treat patient B-cell acute lymphoblastic leukemia return period improvement ( relapse ) . Monoclonal antibody , blinatumomab , may interfere ability tumor cell grow spread . It yet know whether standard combination chemotherapy effective blinatumomab treat relapse B-cell acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Blinatumomab Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare disease free survival ( DFS ) high-risk ( HR ) intermediate-risk ( IR ) relapse B-cell acute lymphoblastic leukemia ( B-ALL ) patient randomize follow induction block 1 chemotherapy receive either two intensive chemotherapy block two 5-week block blinatumomab ( HR/IR randomization ) . II . To compare DFS low risk ( LR ) relapse B-ALL patient randomize follow block 1 chemotherapy receive either chemotherapy alone chemotherapy plus blinatumomab ( LR randomization ) . SECONDARY OBJECTIVES : I . To compare overall survival ( OS ) HR IR relapse B-ALL patient randomize follow induction block 1 chemotherapy receive either two intensive chemotherapy block two 5-week block blinatumomab ( HR/IR randomization ) . II . To compare OS LR relapse B-ALL patient randomize follow block 1 chemotherapy receive either chemotherapy alone chemotherapy plus blinatumomab ( LR randomization ) . TERTIARY OBJECTIVES : I . To compare rate minimal residual disease ( MRD ) &gt; = 0.01 % end block 2 block 3 HR IR relapse B-ALL patient HR/IR randomization . II . To estimate , treatment failure ( TF ) patient previously receive blinatumomab , hematologic complete remission rate ( CR ) , rate MRD &lt; 0.01 % , proportion able proceed hematopoietic stem cell transplant ( HSCT ) CR treatment blinatumomab . III . To assess feasibility safety rapid taper immune suppression subset HSCT patient MRD &gt; = 0.01 % pre- and/or post-HSCT acute graft versus host disease ( aGVHD ) . IV . To evaluate blinatumomab pharmacokinetics ( PK ) explore exposure-response relationship measure safety effectiveness . OUTLINE : All patient receive Block 1 4 week . BLOCK 1 : Patients receive dexamethasone orally ( PO ) twice daily ( BID ) intravenously ( IV ) day 1-5 15-19 ; vincristine sulfate IV 1 minute day 1 , 8 , 15 , 22 ; pegaspargase IV 1-2 hour day 3 17 ; mitoxantrone hydrochloride IV 15-30 minute day 1-2 . Patients central nervous system ( CNS ) 1 CNS2 also receive methotrexate intrathecally ( IT ) day 1 8 . Patients CNS3 isolate CNS relapse also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 1 , 8 , 15 , 22 . High risk intermediate risk patient assign randomization R1 . Low risk patient assign randomization R2 . RANDOMIZATION R1 ( HR IR patient ) : Patients randomize 1 2 treatment arm . ARM A : Patients receive Block 2 4 week , Block 3 4 week , undergo allogeneic HSCT . ARM B : Patients receive Blinatumomab Block 1 5 week , Blinatumomab Block 2 5 week , undergo allogeneic HSCT . RANDOMIZATION R2 ( LR patient ) : Patients randomize 1 2 treatment arm . ARM C : Patients receive Block 2 4 week , Block 3 4 week , Continuation 1 8 week , Continuation 2 8 week , Maintenance . ARM D : Patients receive Block 2 4 week , Blinatumomab Block 2 5 week , Continuation 1 8 week , Blinatumomab Block 3 5 week , Continuation 2 8 week , Blinatumomab Block 3 5 week , Maintenance . BLOCK 2 : Patients receive dexamethasone PO BID IV day 1-5 ; vincristine sulfate IV 1 minute day 1 ; methotrexate IV 36 hour day 8 ; leucovorin calcium IV PO day 10-11 ; pegaspargase IV 1-2 hour day 9 10 ; cyclophosphamide IV 15-30 minute day 15-19 ; etoposide IV 1-2 hour day 15-19 . Patients CNS1 CNS2 also receive methotrexate IT day 8 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 8 22 . BLOCK 3 : Patients receive dexamethasone PO BID IV day 1-5 ; vincristine sulfate IV 1 minute day 1 ; cytarabine IV 3 hour every 12 hour day 1 , 2 , 8 , 9 ; asparaginase intramuscularly ( IM ) IV 1 hour day 2 , 4 , 9 , 11 , 23 ; methotrexate IT day 1 IV 36 hour day 22 ; leucovorin calcium PO IV day 24-25 . Patients CNS1 CNS2 also receive methotrexate IT day 22 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 22 . BLINATUMOMAB BLOCK 1 : Patients blinatumomab IV continuously day 1-28 dexamethasone PO IV day 1 . Patients CNS1 CNS2 also receive methotrexate IT day 15 29 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 15 29 . BLINATUMOMAB BLOCK 2 : Patients blinatumomab IV continuously day 1-28 dexamethasone PO IV day 1 . Patients CNS1 CNS2 also receive methotrexate IT day 8 29 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 8 29 . BLINATUMOMAB BLOCK 3 : Patients blinatumomab IV continuously day 1-28 dexamethasone PO IV day 1 . CONTINUATION 1 &amp; 2 : Patients receive dexamethasone PO BID IV day 1-5 ; vincristine sulfate IV 1 minute day 1 ; mercaptopurine tablet PO day 1-42 ; methotrexate PO day 8 , 15 , 29 , 36 ; leucovorin calcium PO IV day 24-25 ( patient CNS1 , CNS2 , CNS3 ) ; cyclophosphamide IV 15-30 minute day 43 50 ; etoposide IV 1-2 hour day 43 50 ; thioguanine PO daily day 43-49 ; cytarabine IV 1-30 minute subcutaneously ( SC ) day 44-47 51-54 . Patients CNS1 CNS2 also receive methotrexate IT day 1 43 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 1 43 ; methotrexate PO every 6 hour day 22 ; methotrexate IV 36 hour day 22 . MAINTENANCE : Patients receive dexamethasone PO BID IV day 1-5 , 29-33 , 57-61 ; vincristine sulfate IV 1 minute day 1 , 29 , 57 ; mercaptopurine tablet PO day 1-84 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Patients CNS1 CNS2 also receive methotrexate IT day 1 . Patients CNS3 also receive methotrexate IT , hydrocortisone IT , cytarabine IT day 1 . Courses repeat every 12 week 2 year since begin treatment absence disease progression unacceptable toxicity . After completion study treatment , patient follow annually 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>First relapse BALL , allowable site disease include isolated bone marrow , combine bone marrow CNS and/or testicular , isolated CNS and/or testicular ; extramedullary site limit CNS testicles No wait period patient relapse receive standard maintenance therapy Patients relapse frontline therapy phase maintenance must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study Cytotoxic therapy : least 14 day since completion cytotoxic therapy exception hydroxyurea , permit 24 hour prior start protocol therapy , maintenance chemotherapy , intrathecal chemotherapy ( methotrexate strongly prefer ) administer time require diagnostic lumbar puncture establish baseline CNS status Biologic ( antineoplastic ) agent : least 7 day since completion therapy biologic agent ; agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur Stem cell transplant rescue : patient prior stem cell transplant rescue Patient prior treatment blinatumomab With exception intrathecal chemotherapy ( methotrexate strongly prefer ) administer time require diagnostic lumbar puncture establish baseline CNS status , patient receive prior relapsedirected therapy ( i.e. , protocol intend INITIAL treatment first relapse ) Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 , 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 &lt; 2 year : = &lt; 0.6 mg/dL 2 &lt; 6 year : = &lt; 0.8 mg/dL 6 &lt; 10 year : = &lt; 1 mg/dL 10 &lt; 13 year : = &lt; 1.2 mg/dL 13 &lt; 16 year : = &lt; 1.5 mg/dL ( male ) = &lt; 1.4 mg/dL ( female ) &gt; = 16 year : = &lt; 1.7 mg/dL ( male ) = &lt; 1.4 mg/dL ( female ) Direct bilirubin &lt; 3.0 mg/dL Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % radionuclide angiogram All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients Philadelphia chromosome positive/breakpoint cluster region protein ( BCR ) Abelson murine leukemia viral oncogene homolog 1 ( ABL1 ) + ALL eligible Patients Burkitt leukemia/lymphoma mature Bcell leukemia eligible Patients Tlymphoblastic leukemia ( TALL ) /lymphoblastic lymphoma ( TLL ) eligible Patients Blymphoblastic lymphoma ( BLL ) eligible Patients know optic nerve and/or retinal involvement eligible ; patient present visual disturbance ophthalmologic exam , indicate , magnetic resonance imaging ( MRI ) determine optic nerve retinal involvement Patients know one follow concomitant genetic syndrome : Down syndrome , Bloom syndrome , ataxiatelangiectasia , Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome Patients know human immunodeficiency virus ( HIV ) infection Patients know allergy mitoxantrone , cytarabine , etoposide etoposide phosphate ( Etopophos ) Lactating female plan breastfeed Patients pregnant ; pregnancy test require female patient childbearing potential Sexually active patient reproductive potential agree use effective contraceptive method duration study participation Patients preexist significant central nervous system pathology would preclude treatment blinatumomab , include : history severe brain injury , dementia , cerebellar disease , organic brain syndrome , psychosis , coordination/movement disorder , autoimmune disease CNS involvement eligible ; patient history cerebrovascular ischemia/hemorrhage residual deficit eligible ; ( patient history cerebrovascular ischemia/hemorrhage remain eligible provide neurologic deficit resolve ) Patients uncontrolled seizure disorder eligible ; ( patient seizure disorder require antiepileptic drug , well control stable dos antiepileptic drug remain eligible )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>